Skip to main content
. 2006 Mar 28;94(8):1136–1143. doi: 10.1038/sj.bjc.6603055

Table 3. Most frequent toxicities of any grade experienced by patients on this phase II study of erlotinib.

All toxicities n (%) patients n (%) cycles
Rash/desquamation 34 (90) 88 (79)
Lymphopenia 33 (87) 81 (72)
Diarrhoea 23 (61) 69 (62)
Hyperglycaemia 23 (61) 50 (45)
Fatigue/Lethargy 24 (63) 63 (56)
Haemoglobin 30 (79) 78 (70)
Alkaline phosphatase 24 (63) 52 (46)